CD52 and myeloid sarcoma: In this project, we treated EAE models established on C57BL/6 and SJL mice with CD52 antibodies at the peak of disease and analyzed MS-associated pathologies, i.e., neuroinflammation, remyelination and neuroprotection, within 4 days and 14 days after treatments.